×

RNS Number : 8772O

Mode Global Holdings PLC

12 February 2021

 

Mode Global Holdings PLC

 

Mode officially launches its Android app and updates on January trading volumes

 

· Mode confirms launch of much-anticipated   Android app

· Android launch set to accelerate Mode's customer growth

· Trading volumes hit new high in January, 130% surge from December 2020

 

 

Mode Global Holdings PLC ("LSE:MODE") announces that it has officially  launched its much-anticipated Android app, expected to attract thousands of new customers over the coming weeks.

 

The new Android app, which offers the same core features as its existing highly-popular iOS version, enables customers to easily sign up, make free and instant GBP bank transfers and Open Banking top ups in British pounds, and start buying Bitcoin in just minutes. Thanks to Mode's popular Bitcoin Jar product, customers will also be able to get rewarded for holding their Bitcoin.

 

Janis Legler, Chief Product Officer at Mode, said: "After the initial launch of the Mode app on iOS, it quickly became apparent that we needed to release an Android version as soon as possible to satisfy the untapped demand from retail investors for our easy-to-use Bitcoin product. For the past few months, the engineering and design teams have been working really hard to deliver an experience that feels special on Android, yet still unmistakably Mode. We're excited that the time has finally come, and we couldn't be happier to be able to finally bring the Mode experience to everyone."

 

Mode has launched the UK's easiest and fastest way to buy, hold and grow Bitcoin, all in one place. The Mode app, which saw its customer numbers grow by 500% from August to December and ranked no2 in the App Store's UK finance category, has proven highly popular amongst first-time Bitcoin investors, as the app's simplicity and ease-of-use makes it perfect for those starting out their cryptocurrency journey.

 

Jonathan Rowland, Executive Chairman at Mode, said: "Releasing the Android app is a very exciting milestone for the development and expansion of Mode. We have estimated that Android users represent more than half of the cryptocurrency population, presenting a much wider market size to scale and the opportunity to significantly accelerate our user growth. Today marks another key step in our mission to provide investors with access to next-generation Bitcoin products. "

 

Mode reports that January was another record-breaking month in terms of Bitcoin traded on Mode, with volumes growing by more than 130% compared to December 2020. Since August, Mode's trading volumes have grown 110% month-on-month.

 

To celebrate the launch of Android, Mode is increasing its referral program fee from £10 to £20 for 30 days, which means users on both Android and iOS can invite their friends to Mode and earn £20 worth of Bitcoin each. T&Cs apply and are available via https://modeapp.com/referral-program-terms/ .

 

Ends

 

Contact

 

Maitland/AMO (PR): James Isola/Kate Pledger [email protected]

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCLFLLFFLLEBBD

Close

×

RNS Number : 5860O

Immotion Group PLC

10 February 2021

 

Immotion Group plc

 

("Immotion", the "Company" or the "Group")

 

New Contract and Trading Update

 

Immotion Group, the UK-based immersive entertainment group, is pleased to announce it has signed a contract to provide a new Undersea Explorer VR Theatre at Clearwater Marine Aquarium in Florida, USA. This is expected to open in March 2021.

 

The immersive theatre will include interactive pre-show exhibits, as well as a 22-seat VR theatre where customers can enjoy the Group's "Swimming with Humpbacks" VR movie.  The installation will be part of the Aquarium's new Whales: "Living with Giants" exhibit.

 

Clearwater Marine Aquarium is one of the leading aquariums and marine life rescue and research facilities in Florida and was featured in the films Dolphin Tale and Dolphin Tale 2. The facility is dedicated to the rescue, rehabilitation and release of sick and injured marine animals, public education, conservation and research. With over 750,000 annual visitors historically, it has recently completed an $80m upgrade to its facilities and the Undersea Explorer VR Theatre will be a centrepiece of the new exhibit space. 

 

The installation will be focused on whales, including Immotion's interactive "Humpbacks Revealed" exhibit which allows guests to learn more about the amazing anatomy of these whales, as well as "Songs of the Sea" which gives guests a window into the humpback's mesmerizing vocalisations.  The pinnacle of the exhibit will be Immotion's amazing "Swimming with Humpbacks" VR movie, filmed in the Pacific Ocean off Tonga, the first motion-platform VR film to capture mother whales and their calves in their natural habitat. 

 

The Clearwater Marine Aquarium agreement allows for a 50:50 revenue share with the Partner, along with a monthly fee to Immotion to defray installation costs.  The contract will initially be for 12 months, with scope to extend including the addition of new content to refresh the experience for guests over time.

 

Locations in Florida are generally open to the public; though with safety precautions and related restrictions in place.

 

Location Based Entertainment ("LBE") – Update

 

U.S.A

 

In the USA, we have 23 Partner locations.  20 of these are open, with 18 operating our VR installations.  Two further partner locations remain closed completely and a further one partner site is mid renovation.

 

Trading at our operational USA aquarium partner sites is encouraging for the time of year and given the overall trading environment. 

 

Other USA non-aquarium partner sites are trading as expected given the level of restrictions in place and we look forward to those recovering further as and when restrictions are eased in the months ahead.

 

With regard to our site at Shark Reef Aquarium, Mandalay Bay, Las Vegas, a review of the current restrictions is due by the Nevada authorities on 15 February 2021 and given the fall in local Covid cases, the Company is hopeful the current 25% capacity restriction, which has significantly impacted short term revenues, may be relaxed to its pre-November levels and then upwards from there.

 

In terms of future developments, we have seen a significant uplift in enquiries from potential new partners and are in discussions in relation to a number of larger sites in the USA, in line with our stated strategy of focusing on fewer but higher traffic sites, which can support larger interactive installations, and which are a more integral part of the Partner offering.

 

UK

 

Whilst the UK LBE business (including our own ImmotionVR entertainment centres) is sadly still closed, we are hopeful that as progress is made with the UK vaccination programme, we will benefit at least from a strong summer of trading and would hope that we may even see some earlier easing of restrictions.  We believe that there will be considerable pent up consumer demand for out of home entertainment and the UK leisure market should benefit from a significant "staycation" season if it opens up for the summer.

 

Other Territories

 

Our installations at Sealife Sydney and Melbourne are open, and trading is picking up as Australia enters its summer season. In addition, the Company expects to open a Tower Coaster at the landmark Sydney Tower Eye in the next few weeks.

 

Conclusion

 

In conclusion, whilst our LBE business has experienced very challenging trading conditions as a result of the various lockdowns and restrictions, we are increasingly optimistic that as vaccine programmes take hold in the UK and USA, and as we move towards the summer in both countries, we will see a strong recovery. We believe that the longer-term prospects for our LBE business remain attractive.

 

As we stated in our end of year update on 23 December 2020, Q1 of this current year will be very challenging for obvious reasons and we are taking all steps we can, including using the UK furlough scheme and applying for further available USA government support, to mitigate the significant financial impact of restrictions caused by the pandemic. 

 

However, we believe there is cause for optimism looking forward and we will be well placed to benefit significantly from any easing of restrictions.

 

Let's Explore

 

Following the successful UK launch of the Let's Explore home entertainment business in Q4 2020, the Company sold over 11,000 units in the build-up to Christmas.  The quieter post- Christmas period has given us the ability to take a breath and focus on optimising the supply chain, which should see significantly reduced product cost and the opportunity to plan for growth.

 

Stock has been bought forward at sufficient scale to allow us to achieve a circa 40% reduction in product cost and this will support a USA launch of the Let's Explore Oceans product later this month. In addition, the product is now available on both UK Amazon and eBay marketplaces.

 

The Company believes there is a very significant opportunity for Christmas 2021 and, unlike 2020 where we launched the product at very high speed, we will have the ability to plan forward.  The focus is to have all operational, logistical and product elements in place to capitalise on the Christmas 2021 opportunity, as well as opening up new geographies in the meantime.  In addition, we plan to develop new genres as we move through the year.

 

Uvisan  

 

Sales of the UV cabinets continues to grow, with success in a number of sectors including education (schools and universities), film and TV production and businesses utilising VR headsets in both leisure and B2B applications.

 

The Company has invested proceeds from the sale of the UV disinfection cabinets into the creation of a proprietary ambient UV room disinfection system.

 

The new product uses UVC ultraviolet light, combined with a proprietary tablet driven, wireless control and safety system, to offer a simple to install and cost-effective room disinfecting system.

 

The new product has the ability to disinfect an un-occupied room and its surfaces in as little as ten minutes, making it ideal for both overnight use and particularly for rooms where rapid turnaround between user groups is required.  For example, it is ideal for school and university classrooms, offices, multi-user recording and post-production studios, operating theatres and laboratories to name but a few.

 

The system has been installed and tested in a University environment and is currently in the final certification process.

 

Along with the Uvisan UV disinfecting cabinets, the Company will be able to offer a range of products for safe and easy disinfection of rooms, surfaces and equipment and will look to scale up this activity through 2021, working with carefully selected partners.

 

 

Commenting on the agreement with Clearwater Marine Aquarium, Rod Findley, Group Commercial Director, Immotion Group plc said:

 

"We are absolutely delighted to be partnering with Clearwater Marine Aquarium on this milestone installation.  It is a signal that institutions are looking forward to the post-pandemic world and making bold steps to give their guests the newest and most exciting experiences.  We're honoured to be part of the first exhibit to go into the new $80m expansion at the aquarium. With Undersea Explorer operational in March, we will be well poised to take advantage of the Spring and Summer traffic."

 

"As capacity restrictions are lifted, we are confident our Location Based Entertainment business will recover quickly and return back to delivering solid revenues.

 

"As far as new partnerships go, we are very pleased with the level of inbound enquiries we are seeing for larger installations, a number of which we believe will come to fruition during this calendar year".

 

Enquiries:

 For further information please visit  www.immotion.co.uk , or contact: 

 

Immotion Group	Martin Higginson David Marks Rod Findley	Tel: +44 (0) 161 235 8505
WH Ireland Limited (Nomad and Joint Broker)	Adrian Hadden  Darshan Patel Matthew Chan	Tel + 44 (0) 207 220 1666
Shard Capital Partners LLP (Joint Broker)	Damon Heath Erik Woolgar	Tel: +44 (0) 20 7186 9900
Alvarium Capital Partners	Alex Davies	Tel: +44 (0) 207 195 1433

  (Joint Broker)

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon the publication of this announcement via Regulatory Information Service this inside information is now considered to be in the public domain.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCEAKAEFFEFEEA

Close

×

RNS Number : 3810O

Pressure Technologies PLC

09 February 2021

 

09 February 2021

 

 

Pressure Technologies plc

 

("Pressure Technologies" or the "Company")

 

Contract Win for Hydrogen Refuelling Stations

 

Pressure Technologies (AIM: PRES), the specialist engineering group, is delighted to announce that its wholly owned subsidiary, Chesterfield Special Cylinders ("CSC"), has secured a contract with Haskel Hydrogen Group (Haskel), part of the Precision and Science Technologies Segment at Ingersoll Rand Inc. (NYSE:IR) for the supply of high-pressure Type 1 steel vessels to be used for hydrogen storage in three new Hydrogen Refuelling Stations ("HRS").

 

This contract, to be delivered through summer 2021, increases the number of HRS projects secured by CSC for Haskel in Europe.  

 

CSC has designed a specialised high-pressure containment solution for Haskel, which is integrated into their new refuelling station design, the Haskel Geno HRS, and configured to enable cost effective inspection and recertification with maximum availability through life using CSC's Integrity Management services.

 

The Haskel Geno HRS utilises state of the art technology and provides an energy efficient turnkey solution for flexible hydrogen supply, including allowing customers to pay with contactless credit cards.

 

The contract will be rolled out by Unipetrol Group and Bonett Group, with Bonett managing the integration of the hydrogen refuelling stations at existing Unipetrol sites throughout the Czech Republic.  Haskel will deliver the hydrogen refuelling stations and work alongside Bonett as they manage the integration.

 

Working together, CSC and Haskel are fully committed to investment and expansion in global refuelling infrastructure for hydrogen-based mobility and are pleased to celebrate this next step in their close working relationship.

 

Commenting, Chris Walters, Chief Executive of Pressure Technologies plc said:

 

"Our recent successful fundraising was built, in part, on our plans to secure new opportunities in the fast-developing hydrogen energy market and we are delighted that the Chesterfield Special Cylinders team will be supporting Haskel with their new hydrogen refuelling station projects.

 

This contract win demonstrates our ability to develop strong and collaborative customer relationships that deliver safe, innovative and cost-effective hydrogen storage solutions in an exciting and growing market."

 

Darran Heath, General Manager at Haskel Global Hydrogen Systems Group said:

 

"We recognise the strong support Chesterfield Special Cylinders has given us over the past two years and are delighted to confirm this additional order that further cements our relationship.  Hydrogen Refuelling Stations are central to our success and capable suppliers like CSC, with a shared vision on how to unlock the hydrogen opportunities, are the key to reliable and innovative supply now and in future.  We look forward to achieving more success together."

 

Enquiries:

 

Pressure Technologies plc
Chris Walters, Chief Executive [email protected]	Tel: 0114 257 3616
Ingersoll Rand Media	Tel: (818) 556-2528
Irma Aguilar
Houston (Financial PR and Investor Relations) Kate Hoare Anushka Mathew Ben Robinson	Tel: +44 (0) 204 529 0549

 

NOTES TO EDITORS

www.pressuretechnologies.com

With its head office in Sheffield, the Pressure Technologies Group was founded on its leading market position as a designer and manufacturer of high-integrity, safety-critical components and systems serving global supply chains in oil and gas, defence, industrial gases and hydrogen energy markets.

The Group has two divisions,  Chesterfield Special Cylinders and  Precision Machined Components.

Chesterfield Special Cylinders (CSC) –   www.chesterfieldcylinders.com    

●Chesterfield Special Cylinders, Sheffield, includes CSC Deutschland GmbH and Chesterfield Special Cylinders Inc.

  Precision Machined Components (PMC) –       www.pt-pmc.com

●Precision Machined Components includes the Al-Met, Roota Engineering, Quadscot, Precision Engineers and Martract brands.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAVVLFBFLLEBBV

Close

×

RNS Number : 3853O

Surgical Innovations Group PLC

09 February 2021

 

Surgical Innovations Group plc
("Surgical Innovations", "SI" or the "Company")

 

Launch of the Green Surgery Challenge

Event sponsor to promote the use of sustainable products in surgery

 

Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery ("MIS"), announces that Elemental Healthcare Limited, a wholly owned SI subsidiary, was a key sponsor at the launch of the Green Surgery Challenge 2021*, which took place last week.

 

This competition , initiated by Elemental Healthcare and developed by the Centre for Sustainable Healthcare ("CSH"), allows UK operating theatres to present innovative ideas to reduce their Carbon Footprint. The national competition has been organised by the CSH, Royal College of Surgeons England, Royal College of Surgeons of Scotland and NIHR Surgical Med Tech Co-op and is endorsed by a number of significant charities and official bodies. 

 

The Green Surgery Challenge 2021 is an opportunity for the UK's surgical community to recognise the value of sustainable healthcare for surgical conditions, share and promote ways of practicing that are less harmful to the environment and the planet and build social sustainability, transforming surgery for the future. The launch event attracted over 400 delegates.

 

The recording can be accessed here: https://youtu.be/Nb2EimC2-0c

 

As announced in November 2020, SI has an ongoing collaboration with the CSH, enabling the Company to validate the environmental messaging for SI's products and demonstrate the quantifiable benefits in cost and environmental savings from a 'greener' operating room, with particular focus on reducing plastic waste in surgery in the UK and globally.

 

Adam Power, SI Group Development Director, commented: "We are pleased to be part of the Green Surgery Challenge launch, bringing sustainability to the forefront of hospital agendas. We are one of the only significant players in the space with our Resposable TM  product portfolio and are passionate to lead and support innovative ideas to reduce public sector waste and emissions, much of which comes from NHS surgical procedures."

 

*More information on the Green Surgery Challenge 2021 can be found here – Green Surgery Challenge | Centre for Sustainable Healthcare

 

For further information please contact:

 

Surgical Innovations Group plc	www sigroupplc com
David Marsh, CEO	Tel: 0113 230 7597
Charmaine Day, Co Sec & GFC
N+1 Singer (Nominated Adviser & Broker)	Tel: 020 7496 3000
Aubrey Powell / Rachel Hayes/ Iqra Amin
Walbrook PR (Financial PR & Investor Relations)	Tel: 020 7933 8780 or [email protected]
Paul McManus / Lianne Cawthorne	Mob: 07980 541 893 / 07584 391 303

 

About Surgical Innovations Group plc

The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.

 

We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part re-usable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.

 

Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.

 

In addition, we design and develop medical devices for carefully selected OEM partners, and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.

 

We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs in the operating theatre environment.

 

The Group currently employs approximately 100 people across two sites in the UK.  Product design, engineering and manufacturing are carried out at the SI site in Yorkshire. Commercial activities including marketing, UK distribution and international sales and marketing are based at Elemental Healthcare in Berkshire.

 

Further information

Further details of the Group's businesses are available on the following websites:

www.sigroupplc.com

www.surginno.com  

www.elementalhealthcare.co.uk

To receive regular updates by email, please contact  [email protected] .

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAMZGGZMRNGMZZ

Close

×

RNS Number : 9322N

Panoply Holdings PLC (The)

04 February 2021

 

4 February 2021

 

The Panoply Holdings PLC

("The Panoply", or the "Group")

 

Contract wins and update on Foundry4

 

The Panoply Holdings PLC (AIM: TPX), the technology-enabled services group focused on digital transformation, announces it has recently won two separate contracts in partnership with Mastek, a global IT player, worth more than £7m over the life of the contracts (the "Contracts").

 

Contract wins

 

The Contracts, which run for two years and have been awarded by the NHS Business Services Authority, comprise a £6m framework agreement to provide capabilities to support the organisation's digital transformation agenda and a £1.2m contract to be its overseas digital health delivery partner.

 

Update on Foundry4

 

The Group is pleased to announce that Difrent will be integrated into Foundry4 with effect from 1 April 2021 at which time Rachel Murphy, current CEO of Difrent, will become CEO of Foundry4. Rachel brings a wealth of delivery experience from across the public sector and the healthcare market, providing the foundations for further expansion into this target market for the Group.

 

James Herbert, the current CEO of Foundry4, will take on the role of Strategic Partnerships Director, responsible for the Group's relationships with Microsoft, Amazon (AWS) and Google (GCP). Foundry4's relationships with these key technology platforms are critical to its success. Foundry4 recently attained a Microsoft Gold Cloud Platform competency, demonstrating a "best-in-class" ability and commitment to meet Microsoft Corp. customers' evolving needs in today's mobile-first, cloud-first world as well as distinguishing itself within Microsoft's partner ecosystem. Becoming a Microsoft Gold Partner will allow Foundry4 to combine strengths with Microsoft, speeding up deployment and improvement of Microsoft Azure environments.

 

Neal Gandhi, CEO of The Panoply, said:

 

"These contract wins represent a step-change in our reach into healthcare, a key growth sector for the Group. We look forward to working with Mastek to support the NHS BSA with its ongoing digital transformation agenda. 

 

We are also delighted that Difrent, the company whose approach has so impressed to secure these wins, will be joining our Foundry4 brand and that Rachel Murphy will be leading it forward as CEO. With her extensive experience driving digital change, Foundry4 is well placed to strengthen its reputation as a leading provider in digital transformation across the public and private sectors."

 

Rachel Murphy, CEO designate of Foundry4 said:

 

"Even from Difrent's relatively short time as part of the Group, the substantial opportunities available through collaboration and combination among the different businesses is clear.

 

In my role as CEO of Foundry4, I am excited to leverage the varied skills and technical expertise we have in our possession to expand the Group's reach across the markets in which we operate".

 

 

Enquiries:

 

The Panoply Holdings Neal Gandhi (CEO) Oliver Rigby (CFO)   Stifel Nicolaus Europe Limited (Nomad and Joint Broker)	Via Alma PR     +44 (0)207 710 7600
Fred Walsh Alex Price
Dowgate Capital Limited (Joint Broker) James Serjeant David Poutney	+44 (0)203 903 7715
Alma PR (Financial PR) Susie Hudson Josh Royston Harriet Jackson	[email protected] +44 (0)203 405 0205

 

 

 

About The Panoply

 

The Panoply is a technology-enabled services group, built to service clients' digital transformation needs. Founded in 2016, with the aim of identifying and acquiring best-of-breed specialist information technology, design and innovation consulting businesses, the Group collaborates with its clients to deliver the technology outcomes they're looking for at the pace that they expect and demand.

The Group is being increasingly recognised as a leading alternative digital transformation provider to the UK public services sector, with c.70% of its client base representing the public sector and c.30% representing the commercial sector.

More information is available at www.thepanoply.com

 

About Foundry4

 

Foundry4 helps organisations in highly regulated sectors harness technology to solve complex challenges. Its deep technical expertise covers all areas of the digital spectrum, from intelligent automation and user centred design, to high quality product engineering teams and agile coaching.

 

Partnering with enterprise organisations, Foundry4 draw on extensive technology and sector knowledge to help them harness the true value of cloud and data.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

CNTBIGDDXDGDGBX

Close

×

RNS Number : 6341N

MelodyVR Group PLC

02 February 2021

 

REACH

MelodyVR Group PLC

("MVR" or the "Company")

Napster B2B Contract Renewals and Platform Metrics

MelodyVR Group PLC (AIM:MVR), a leading music company and operator of the MelodyVR and Napster platforms, is pleased to announce key contract renewals with Napster's business to business partners and release metrics for the Napster platform for the year ending 31 December 2020;

· Amendment to the platform services agreement with SONOS, one of the world's leading sound experience brands, covering the expansion of ad-supported SONOS Radio in 14 new territories (UK, Ireland, France, Germany, Italy, The Netherlands, Sweden, Switzerland, Austria, Belgium, Denmark, Norway, Australia, New Zealand). The SONOS Radio service, which is one of more than 100 streaming services available on the SONOS platform,  is now the 3rd most streamed service on SONOS since its launch in April 2020;

 

· Renewal of the technology and platform services agreement with Panasonic Corporation (Japan) to March 2022, providing application development and integration of Napster services with Panasonic's HomeX smart home music services;

 

· Renewal of the digital media services agreement with Telefonica Germany to December 2022, including a 2-year extension of the Napster music service for O2 subscribers and Aldi Talk service subscribers in Germany.

 

These contract renewals are expected to secure revenues of c.$16 million in aggregate over the course of the next 2 years.

 

We are also pleased to report the following engagement metrics for the Napster platform for the year ended 31 December 2020. These metrics demonstrate user engagement with the platform and a basis on which to attract new revenue generating users and B2B contracts.

· 126% increase in total platform users at December 2020, including subscribers from PaaS services, to 5.7 million (December 2019: 2.5 million)

· 15% increase in platform average monthly active users, including subscribers from PaaS services, to 1.2 million (FY19: 1.0 million)

· 10.5 billion total plays (FY19: 10.8 billion) and 306.5 million listening hours (FY19: 328.2 million)

In addition, we are pleased to report further expansion in the catalogue of tracks available on the platform thus strengthening the proposition and the depth of content available to Napster's user base.

· 25% increase in available tracks on the Napster D2C and B2B platform at the year end to 105 million (FY19: 84 million)

· 30% increase in total unique artists available on the platform at the year end to 4.6 million (FY19: 3.5 million)

Anthony Matchett, Group CEO said:

"The continued adoption of music streaming is creating meaningful B2B growth opportunities for Napster's platform-as-a-service business. These latest contract updates follow a very successful 2020 with 130% growth in PaaS revenues from partners like Sonos, Huawei, BMW, Sony, Rakuten and others.

We are pleased by the encouraging growth statistics that the Napster service demonstrated throughout 2020, including a broadening of the Napster music library, that now contains over 105 million tracks. Following MelodyVR's successful acquisition of the Napster/Rhapsody business, we will leverage the existing technologies of both Napster and MelodyVR, alongside the best content and functionality from each business, to create a new music platform during the course of 2021. Napster has seen increases in active users and in-app engagement during the last twelve months, and we believe this strong consumer appetite will continue into 2022 and that the launch of our new product will benefit from consumer's increased appetite for digital entertainment.

For further information please contact; 

MelodyVR Group PLC
Anthony Matchett, Group CEO      [email protected]

Arden Partners plc: 

Nominated Advisor and Broker      Tel: +44 (0) 20 7614 5900

Corporate Finance: Ruari McGirr / Ben Cryer

Corporate Broking: Simon Johnson 

Notes to Editors:

www.melodyvr.com

www.napster.com

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAUPUPGPUPGPPG

Close

×

RNS Number : 2843N

Intuitive Investments Group plc

29 January 2021

 

Intuitive Investments Group plc

("IIG" or the "Company")

 

Portfolio company BioQ Pharma receives CE mark

EU approval for BioQ's next generation medication dispenser

 

Intuitive Investments Group plc (AIM: IIG), a closed-end investment company focussed on the life sciences sector, announces that its portfolio company, BioQ Pharma Incorporated ("BioQ"), has received CE mark approval for its single-use medication dispenser, the OneDose ReadyfusOR Gen2.

 

The OneDose ReadyfusOR Gen2 is the second generation of BioQ's original OneDose ReadyfusOR infusion system and was developed to further improve patient convenience. The new system is smaller and lighter than the original product. For the full announcement, visit: https://bioqpharma.com/news/article_20210127

 

BioQ is a well-established, commercial-stage, medical device and pharmaceutical company, addressing the infusible drugs market. BioQ's proprietary InveniousTM platform comprises a "connect-and-go" drug-device system combination, which can be utilised to improve the delivery of infusible medicines. The key benefits of the platform include reduced cost and complexity compared to current infusion techniques. Further information on BioQ can be found at the company's website: www.bioqpharma.com .

 

On 21 January 2021, IIG announced its investment of US$1 million by way of unsecured convertible loan notes in BioQ, the Company's second investment from its pipeline of opportunities following its successful IPO in December 2020.

 

 

For further information, please contact:

 

Intuitive Investments Group plc	www.iigplc.com
David Evans	Via Walbrook PR
Strand Hanson Limited – Nominated Adviser	+44 (0)20 7409 3494
James Harris / James Dance / James Bellman
Turner Pope Investments (TPI) Ltd – Broker	+44 (0)20 3657 0050
Ben Turner / James Pope / Andrew Thacker
Walbrook PR Limited – Media & Investor Relations	+44 (0)20 7933 8780 or [email protected]
Paul McManus	+44 (0) 7980 541 893

 

 

About Intuitive Investments Group plc

 

The Company is a newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRABIGDBIUDDGBI

Close

×

RNS Number : 3778M

Intuitive Investments Group plc

21 January 2021

 

 

Intuitive Investments Group plc

("IIG" or the "Company")

Investment in BioQ Pharma

Intuitive Investments Group plc (AIM:IIG), a closed-end investment company focussed on the life sciences sector, is pleased to announce its investment of US$1 million by way of unsecured convertible loan notes ("CLNs") in BioQ Pharma Incorporated ("BioQ").

BioQ is a well-established, commercial-stage, medical device and pharmaceutical company, addressing the infusible drugs market. BioQ's proprietary InveniousTM platform comprises a "connect-and-go" drug-device system combination, which can be utilised to improve the delivery of infusible medicines.  BioQ's platform includes a bespoke unit-dose delivery solution for infusible drugs, whereby a diluent delivery system and administration line are combined in one self-contained, ready-to-use presentation. The key benefits of the platform include reduced cost and complexity compared to current infusion techniques. Further information on BioQ can be found at the company's website: www.bioqpharma.com .

IIG's investment in BioQ consists of US$1 million of CLNs maturing on 1 November 2021. The terms of the CLN include a coupon of 10% that is accrued and paid on conversion or repayment, warrant coverage, and provisions for conversion into new equity at the time of a qualifying future fundraise (at a 35 per cent. discount to the price of such fundraise) or at maturity.

BioQ is the Company's second investment from its pipeline of opportunities, and follows its successful IPO in December 2020.

David Evans personally invested US$75,000 in Bio Q's Series B funding round in 2009 which is less than an 0.5% interest in the company. Accordingly, David Evans did not vote as a member of the Board of IIG approving the transaction.  

In the nine months ended 30 September 2020, BioQ made a net loss of US$5.9million and, as at 30 September 2020, had net liabilities of approximately US$32 million.

David Evans, Chairman of IIG, said:

"We are hugely impressed by BioQ and what Josh Kriesel and the BioQ team have built in the US and Europe. We strongly believe the adoption by the healthcare providers of BioQ's " Pharmacy in a Box" which is also a "connect-and-go" delivery system will continue to accelerate in the near term. Our investment demonstrates IIG's ability to act quickly and opportunistically when compelling opportunities arise."

 

For further information, please contact:

 

Intuitive Investments Group plc
David Evans	Via Walbrook PR
Strand Hanson Limited – Nominated Adviser	+44 (0) 20 7409 3494
James Harris / James Dance / James Bellman
Turner Pope Investments (TPI) Ltd – Broker	+44 (0) 20 3657 0050
Ben Turner / James Pope / Andrew Thacker
Walbrook PR Limited – Media & Investor Relations	+44 (0)20 7933 8780 or [email protected]
Paul McManus	+44 (0) 7980 541 893

 

 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.

 

 

About Intuitive Investments Group plc

 

The Company is a newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCDBLFLFFLLBBD

Close

×

RNS Number : 3738M

Image Scan Holdings PLC

21 January 2021

 

REACH – This is a non-regulatory announcement.

21 January 2021

 

IMAGE SCAN HOLDINGS PLC

("Image Scan" or the "Company")

 

CONTRACT TO SUPPLY PORTABLE X-RAY SYSTEMS TO THE ROYAL AIR FORCE

 

Image Scan (AIM: IGE), specialists in the field of X-ray imaging for the security and industrial inspection markets, announces the award of a contract to supply three portable X-ray scanning systems to the Royal Air Force.

 

The systems to be supplied are the ThreatScan®-LSC, a combination package including a large format ThreatScan®-LS1 panel, a compact ThreatScan®-LS3 panel with back-pack, a tablet PC imaging station and the I-Gen generator. This combination system provides great deployment flexibility for different threat scenarios.

 

The award is the Company's first contract with the RAF.

 

Bill Mawer, Chairman and Chief Executive Officer of Image Scan commented: "I am delighted by this contract award. It provides a key reference with the UK Government that should both help us to achieve further UK sales and support our international marketing campaigns. The ThreatScan®-LSC 'Combi' system is our highest value portable X-ray package, and we look forward to further sales of this configuration."

 

For further information on the Company, please visit:   www.ish.co.uk   and for further information on its products, please visit:   www.3dx-ray.com

 

Enquiries:
Image Scan Holdings plc William Mawer, Chairman and Chief Executive Officer Sarah Atwell King, Finance Director and Company Secretary	Tel: +44 (0) 1509 817 400 [email protected]

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAURRBRAAUAUAR

Close

×

RNS Number : 2326M

DeepMatter Group PLC

20 January 2021

 

20 January 2021

 

DeepMatter Group plc

("DeepMatter", the "Company" or "the Group")

 

DeepMatter subsidiary signs data licensing agreement with the Life Science business of Merck

DeepMatter Group plc, the AIM-quoted company focusing on digitising chemistry, is pleased to announce that one of its wholly owned subsidiaries has entered into a multi-year, limited-use data licensing agreement with the Life Science business of Merck to provide proprietary chemical structure and reaction data content to Merck's selected application.

Merck, a leading science and technology company, operates across Healthcare, Life Science and Performance Materials.  The terms of the data license agreement have not been disclosed.

 

Mark Warne, CEO of DeepMatter commented : "We are delighted to have entered into this license with Merck, a company dedicated to making research and biotech simpler, faster and safer."

 

 

For more information, please contact:

 

DeepMatter Group plc	T: 0141 548 8156
Mark Warne, Chief Executive Officer
Canaccord Genuity Limited (Nominated Advisor and Broker)	T:  020 7523 8000
Bobbie Hilliam / Angelos Vlatakis
Alma PR	T: 020 3405 0205
Caroline Forde / Harriet Jackson / Kieran Breheny	[email protected]

 

About DeepMatter Group plc  

DeepMatter's long term strategy is to integrate chemistry with technology, thereby enabling a greater use of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through robotics. It has developed and is commercialising data rich platform technologies, including software and laboratory hardware, focused on applications to improve R&D productivity and discovery using Machine Learning / Artificial Intelligence.  

DeepMatter's technologies allow chemistry experiments to be accurately and systematically recorded, coded and entered into a shared data cloud. They are designed to enable chemists to work together effectively; sharing the details of their experiments from anywhere and in real-time, so that work is not needlessly duplicated, time and money wasted, and ultimately so new discoveries may be made faster.  

About Merck

Merck, a leading science and technology company, operates across Healthcare, Life Science and Performance Materials. Around 57,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck generated sales of €16.2 billion in 66 countries.

 

www.merckgroup.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

CNTKKLFFFFLBBBE

Close